Patents by Inventor Bo-gyou Kim

Bo-gyou Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarker PNCK for predicting effect of a dual-targeting agent
    Patent number: 10578621
    Abstract: A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: March 3, 2020
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Ji Min Lee, Bo Gyou Kim, Kyung Ah Kim, Seung Ja Oh
  • Polypeptide, anti-VEGF antibody, and anti-c-Met/anti-VEGF bispecific antibodies comprising the same
    Patent number: 10246507
    Abstract: A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: April 2, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seung Hyun Lee, Soo Yeon Jung, Bo Gyou Kim, Seung Ja Oh, Ji Min Lee
  • Biomarker Hsp90 for predicting effect of a c-Met inhibitor
    Patent number: 9956244
    Abstract: A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: May 1, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Ji Min Lee, Bo Gyou Kim, Seung Ja Oh, Kyung Ah Kim, Saet Byoul Lee, Jae Woong Hwang
  • Combination therapy using dual inhibitor of c-MET and EGFR and IGF-1R inhibitor
    Patent number: 9943596
    Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: April 17, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Jimin Lee, Bo Gyou Kim, Seungja Oh, Kyung Ah Kim, Powei Lin, Saet Byoul Lee
  • Biomarker TFF1 for predicting effect of C-MET inhibitor
    Patent number: 9850537
    Abstract: A method of predicting an effect of a c-Met inhibitor and/or selecting a subject for application of a c-Met inhibitor using TFF1, a method of monitoring an effect of a c-Met inhibitor using TFF1, and a method of treating and/or preventing cancer including administering a c-Met inhibitor to the selected subject.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: December 26, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Bo Gyou Kim, Eunjin Lee, Kyung Ah Kim, Tae Jin Ahn
  • Anti-c-Met/anti-Ang2 bispecific antibody
    Patent number: 9808507
    Abstract: An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: November 7, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Seungja Oh, Kyung Ah Kim, Bo Gyou Kim, Seung Hyun Lee, Ji Min Lee
  • Combination therapy for the treatment of cancer using an anti-C-met antibody
    Patent number: 9567641
    Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: February 14, 2017
    Assignees: SAMSUNG ELECTRONICS CO., LTD., GEORGETOWN UNIVERSITY
    Inventors: Bo Gyou Kim, Shangzi Wang, Ji Min Lee, Kyung Ah Kim, Louis M. Weiner
  • Marker for determining effects of anti-c-Met antibody and method of determining effects of anti-c-Met antibody using the marker
    Patent number: 9535055
    Abstract: There are provided a composition for determining the efficacy of a c-Met antibody including marker genes and a method for determining the efficacy of a c-Met antibody using the marker genes.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: January 3, 2017
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Bo Gyou Kim, Kyung Ah Kim
  • COMBINATION THERAPY USING DUAL INHIBITOR OF C-MET AND EGFR AND IGF-1R INHIBITOR
    Publication number: 20160144028
    Abstract: A method of preventing and/or treating a cancer, the method including co-administering a dual inhibitor of c-Met and EGFR (hereinafter, ‘c-Met/EGFR dual inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met/EGFR dual inhibitor
    Type: Application
    Filed: November 23, 2015
    Publication date: May 26, 2016
    Inventors: Jimin Lee, Bo Gyou Kim, Seungja Oh, Kyung Ah Kim, Powei Lin, Saet Byoul Lee
  • POLYPEPTIDE, ANTI-VEGF ANTIBODY, AND ANTI-C-MET/ANTI-VEGF BISPECIFIC ANTIBODIES COMPRISING THE SAME
    Publication number: 20160090427
    Abstract: A polypeptide, an anti-VEGF antibody and an anti-c-Met/anti-VEGF bispecific antibody, which includes the polypeptide, a pharmaceutical composition including the antibody, and a method of treating cancer using the antibody.
    Type: Application
    Filed: September 29, 2015
    Publication date: March 31, 2016
    Inventors: Seung Hyun Lee, Soo Yeon Jung, Bo Gyou Kim, Seung Ja Oh, Ji Min Lee
  • ANTI-C-MET/ANTI-ANG2 BISPECIFIC ANTIBODY
    Publication number: 20160053025
    Abstract: An anti-c-Met/anti-Ang2 bispecific antibody including (a) an anti-c-Met antibody or antigen-binding fragment thereof and (b) an anti-Ang2 antibody or antigen-binding fragment thereof, a pharmaceutical composition including the anti-c-Met/anti-Ang2 bispecific antibody, and a method using the anti-c-Met/anti-Ang2 bispecific antibody.
    Type: Application
    Filed: August 25, 2015
    Publication date: February 25, 2016
    Inventors: Seungja Oh, Kyung Ah Kim, Bo Gyou Kim, Seung Hyun Lee, Ji Min Lee
  • BIOMARKER HSP90 FOR PREDICTING EFFECT OF A C-MET INHIBITOR
    Publication number: 20160030559
    Abstract: A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.
    Type: Application
    Filed: July 30, 2015
    Publication date: February 4, 2016
    Inventors: Ji Min LEE, Bo Gyou KIM, Seung Ja OH, Kyung Ah KIM, Saet Byoul LEE, Jae Woong HWANG
  • BIOMARKER PNCK FOR PREDICTING EFFECT OF A DUAL-TARGETING AGENT
    Publication number: 20160033518
    Abstract: A biomarker PNCK for predicting an efficacy of a dual-targeting agent that targets both c-Met and EGFR and a method of predicting an effect of a dual-targeting agent that targets both c-Met and EGFR, selecting the subject for application of a dual-targeting agent that targets both c-Met and EGFR, or monitoring an effect of a dual-targeting agent that targets both c-Met and EGFR, including measuring a level of a PNCK and/or a PNCK coding gene.
    Type: Application
    Filed: July 30, 2015
    Publication date: February 4, 2016
    Inventors: Ji Min Lee, Bo Gyou Kim, Kyung Ah Kim, Seung Ja Oh
  • Method of treating solid cancers using anti-c-Met antibody and sorafenib combination therapy
    Patent number: 9233155
    Abstract: Provided is a method of combination therapy for prevention or treatment of a cancer including or consisting essentially of co-administering sorafenib and an anti-c-Met antibody or an antigen-binding fragment thereof to a subject. The method of combination therapy can achieve an excellent synergistic effect and lower the effective dose of the anti-c-Met antibody, thereby enabling a more effective cancer treatment.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: January 12, 2016
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Bo Gyou Kim, Ji Min Lee, Kyung Ah Kim, Yun Ju Jeong
  • Use of LRIG1 as a biomarker for identifying a subject for application of anti-c-Met antibodies
    Patent number: 9213032
    Abstract: A method of identifying a cell sample or subject suitable for treatment with an anti-c-Met antibody or antigen-binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining the presence of LRIG1 in a cell sample from the subject, as well as related methods and compositions.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: December 15, 2015
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Ji Min Lee, Kyung Ah Kim, Bo Gyou Kim
  • Use of Cbl as biomarker for identifying subject suitable for treatment with anti-c-Met antibody
    Patent number: 9213031
    Abstract: A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: December 15, 2015
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Ji Min Lee, Kyung Ah Kim, Bo Gyou Kim, Young Mi Oh, Saet Byoul Lee, Yun Ju Jeong
  • Method of treating cancer using anti-c-Met antibody and FGFR inhibitor combination therapy
    Patent number: 9192666
    Abstract: Provided is a method for prevention or treatment of a cancer, comprising co-administering (a) an FGFR inhibitor and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof, wherein the anti-c-Met antibody or the antigen-binding fragment thereof specifically binds to an epitope comprising 5 or more contiguous amino acids within the SEMA domain of c-Met protein.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: November 24, 2015
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Bo Gyou Kim, Ji Min Lee, Kyung Ah Kim, Yun Ju Jeong
  • BIOMARKER TFF1 FOR PREDICTING EFFECT OF C-MET INHIBITOR
    Publication number: 20150212077
    Abstract: A method of predicting an effect of a c-Met inhibitor and/or selecting a subject for application of a c-Met inhibitor using TFF1, a method of monitoring an effect of a c-Met inhibitor using TFF1, and a method of treating and/or preventing cancer including administering a c-Met inhibitor to the selected subject.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 30, 2015
    Inventors: Bo Gyou Kim, Eunjin Lee, Kyung Ah Kim, Tae Jin Ahn
  • COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING AN ANTI-C-MET ANTIBODY
    Publication number: 20150010575
    Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.
    Type: Application
    Filed: July 3, 2014
    Publication date: January 8, 2015
    Inventors: Bo Gyou KIM, Shangzi Wang, Ji Min Lee, Kyung Ah Kim, Louis M. Weiner
  • METHOD OF COMBINATION THERAPY USING ANTI-C-MET ANTIBODY AND FGFR INHIBITOR
    Publication number: 20140308284
    Abstract: Provided is a method for prevention or treatment of a cancer, comprising co-administering (a) an FGFR inhibitor and (b) an anti-c-Met antibody or antigen-binding fragment thereof to a subject in need thereof, wherein the anti-c-Met antibody or the antigen-binding fragment thereof specifically binds to an epitope comprising 5 or more contiguous amino acids within the SEMA domain of c-Met protein.
    Type: Application
    Filed: April 1, 2014
    Publication date: October 16, 2014
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: BO GYOU KIM, JI MIN LEE, KYUNG AH KIM, YUN JU JEONG